Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT ID: NCT05550298

Last Updated: 2025-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-13

Study Completion Date

2029-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).

Primary Objective

To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.

Secondary Objectives:

* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors.
* To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will collect a nasal swab and blood sample from the participant when the participant is enrolled on the study and if the participant develops a RVI in the first year after transplant. The investigators will collect a blood sample 100 days after the participant's transplant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic Cell Transplant Solid Organ Transplant Respiratory Viral Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hematopoietic Cell Transplantation (HCT)

Early and accurate diagnosis of respiratory viral infections (RVIs) in children and adolescents who have undergone HCT is important for improving outcomes. The investigators are doing this study to understand more about how RVIs affect children who receive a transplant.

No interventions assigned to this group

Solid Organ Transplant (SOT)

Early and accurate diagnosis of respiratory viral infections (RVIs) in children and adolescents who have undergone SOT is important for improving outcomes. The investigators are doing this study to understand more about how RVIs affect children who receive a transplant.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Less than 18 years at the time of anticipated transplant
* Participant meets one of the following criteria:

1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or
2. Scheduled to or received solid organ transplant within 7 days before or after enrollment
* Participant is receiving care at the time of enrollment at one of the study participating institutions.
* Parent/guardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.


* Donor for HCT recipient enrolled on the VIPER study.
* Willing and able to provide informed consent.

Exclusion Criteria

None


* Is not an HCT donor for a participant enrolled on the VIPER study.
* Not available to provide pre-transplant research blood sample.
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Jude Children's Research Hospital

OTHER

Sponsor Role collaborator

Seattle Children's Hospital

OTHER

Sponsor Role collaborator

The Children's Hospital at Montefiore

OTHER

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Arkansas Children's Hospital Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabriela Maron, MD

Role: PRINCIPAL_INVESTIGATOR

St. Jude Children's Research Hospital

William J. Steinbach, MD

Role: PRINCIPAL_INVESTIGATOR

Arkansas Children's Hospital Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham's (UAB)

Birmingham, Alabama, United States

Site Status RECRUITING

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status RECRUITING

Children's National Medical

Washington D.C., District of Columbia, United States

Site Status RECRUITING

University if Miami

Miami, Florida, United States

Site Status RECRUITING

Emory and Children's Healthcare of Atlanta

Atlanta, Georgia, United States

Site Status RECRUITING

University of Chicago Medicine Comer Children's Hospital

Chicago, Illinois, United States

Site Status RECRUITING

University of Louisville

Louisville, Kentucky, United States

Site Status RECRUITING

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status RECRUITING

C.S. Mott Children's Hospital

Ann Arbor, Michigan, United States

Site Status RECRUITING

Children's Hospital of Michigan

Detroit, Michigan, United States

Site Status RECRUITING

University of Minnesota

Minneapolis, Minnesota, United States

Site Status RECRUITING

Washington University

St Louis, Missouri, United States

Site Status RECRUITING

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status RECRUITING

The Children's Hospital at Montefiore

The Bronx, New York, United States

Site Status RECRUITING

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status RECRUITING

Nationwide Children's Hospital

Columbus, Ohio, United States

Site Status RECRUITING

UPMC

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status RECRUITING

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Site Status RECRUITING

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Site Status RECRUITING

UT Le Bonheur

Memphis, Tennessee, United States

Site Status RECRUITING

Cook Children's

Fort Worth, Texas, United States

Site Status RECRUITING

Baylor College of Medicine

Houston, Texas, United States

Site Status RECRUITING

MD Anderson Center Center

Houston, Texas, United States

Site Status RECRUITING

UTHealth Houston

Houston, Texas, United States

Site Status RECRUITING

Seattle Childrens

Seattle, Washington, United States

Site Status RECRUITING

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gabriela Maron, MD

Role: CONTACT

866-278-5833

William J. Steinbach, MD

Role: CONTACT

501-364-5262

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maria Rueda Altez, MD

Role: primary

205-638-2599

William J. Steinbach, MD

Role: primary

501-364-5262

Benjamin Hanisch, MD

Role: primary

202-476-5051

Ivan Gonzalez, MD

Role: primary

Kathryn Goggin, MD

Role: primary

404-785-5437

Madan Kumar, MD

Role: primary

773-702-7087

Victoria Statler, MD

Role: primary

Tanvi Sharma, MD

Role: primary

617-919-2900

Jason Weinberg,, MD

Role: primary

734-764-6265

Arora Harbir, MD

Role: primary

313-745-5219

Beth Thielen, MD., PhD

Role: primary

612-626-5637

Carol M Kao, MD

Role: primary

314-273-4687

Kari Neeman, MD

Role: primary

402-559-4000

Marc Foca, MD

Role: primary

718-741-2470

Lara Danziger-Isakov, MD

Role: primary

513-636-7499

Masako Shimamura, MD

Role: primary

614-722-4452

Johnathan Albert, MD

Role: primary

412-692-3021

Isaac Cason

Role: backup

412-692-7351

Lauren Powell, DO

Role: primary

843-792-9909

Timothy Minniear, MD

Role: primary

901-287-5374

Gabriela Maron, MD

Role: primary

866-278-5833

Timothy Minniear, MD

Role: primary

901-287-5374

[email protected] S. Whitworth, MD

Role: primary

682-885-1485

Elizabeth Moulton, MD

Role: primary

832-824-4330

Natalie D Garnes, MD

Role: primary

713-745-0855

Jennifer Jackson

Role: backup

346-725-1272

Ramia Zakhour, MD

Role: primary

713-500-5714

Alpana Waghmare, MD

Role: primary

206-987-6558

Anna Huppler, MD

Role: primary

414-337-7090

Related Links

Access external resources that provide additional context or updates about the study.

http://www.stjude.org

St. Jude Children's Research Hospital

http://www.stjude.org/protocols

Clinical Trials Open at St. Jude

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

7R01AI159684-02

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2022-08554

Identifier Type: OTHER

Identifier Source: secondary_id

VIPER

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.